June 10, 2019
The conclusions from ICER’s cost-effectiveness evaluations can impact patients’ access to needed treatments. It is imperative, consequently, that ICER’s value assessment…
May 22, 2019
As an oral formulation, semaglutide creates convenience benefits for patients that could save time and increase their overall productivity. Specifically, oral semaglutide…
May 1, 2019
The value created by treatment success, in terms of patient outcomes, health care savings, reduced costs on caregivers, and the…
February 21, 2019
The story has become a familiar one. A patient with a chronic condition works with his or her doctor to find the right treatment. The condition is stabilized, manageable.
October 23, 2018
Mitigating the high cost of severe asthma requires, in part, access to the appropriate medications. Those include the five monoclonal…
October 17, 2018
The Institute for Clinical and Economic Review says new medicine for uncontrolled asthma isn’t worth its cost. But its analysis…
June 4, 2018
As noted in ICER’s scoping document, uncontrolled asthma is a substantial problem that, according to the Centers for Disease Control and Prevention, afflicts 38.4 percent of children with asthma and 50 percent of adults with asthma. It is not clear from the scoping document, however, that ICER will adequately incorporate into its analysis several key issues associated with uncontrolled asthma.
May 25, 2018
The 340B Drug Pricing Program was designed to encourage health care facilities to provide care for uninsured or underinsured patients.…
May 2, 2018
The Institute for Clinical and Economic Review says new CGRP inhibitor treatments for chronic and episodic migraine probably won’t be…
May 2, 2018
Migraine is one of the most prevalent neurological disorders worldwide, associated with substantial health, sociological and economic consequences. Yet ICER’s…
